Lisa Hallock finally started to see continuous results in the complex semi -glucide, an active ingredient used in ozempic after trying to reduce weight for the lifetime. As three busy mothers who attempted diet programs such as other weight loss drugs, strict calorie restrictions, and weight watchers, Hallock was interested by GLP-1, but I found out that it could not be accessible.
“It was really too expensive. Of course, my insurance didn’t deal with it, so it’s complicated to me. ”
Complex drugs are allowed when there is a significant tribe. HALLOCK uses a compound version of HIMS & HERS, paying $ 165 per month for drugs, not including $ 1,000 per month in a month of brand name. According to Hallock, the reduction of weight and reducing food noise without a strict diet allowed her “new level of freedom.”
However, it can be removed from the imminent FDA change around the composite drug.
According to the FDA, classes of drugs such as semaglutide and ozempic and classes of drugs such as Mounjaro are no longer supplying, so they prohibit composite. According to the company’s statements, a company that supplies the composite version of the drug is considered a violation just a few months ago.
Hallock said, “This is just a face hit.
She is not the only person. Sources say that this can be a regulation that affects hundreds of thousands of people.
“We have a lot of people who use this drug, and now we will potentially take them. But we have no solutions and people have to depend on them.
In addition, many companies such as HIMS & HERS, Futurhealth, WISP, RO, etc. have a risk of building businesses for complexes. But many companies had a big impact on sharing their strategies.
John Levan, a co -founder of Futurheealth, a remote healthy company that provides beneficial drugs and nutritional coaching, said, “We will closely monitor the evolutionary regulations for composite weight loss drugs and continue to adjust our strategies as needed. He said the company has not yet changed its model.
The CEO of weight watchers said: “Recent news does not mean short -term change in existing treatment plans or drug availability. As the availability develops, we are ready to support members with alternative options, including other complex drugs such as FDA approval, brand GLP-1, and Liraglutide. ”
Monica Cepak, meanwhile, said the company has doubled alternatives, including brand name pharmaceuticals and GLP-1 reinforcement supplements.
“We will cooperate with patients to introduce products that can be used with patients, and we will work with pharmacy partners to create new solutions.”
As concerns increase, HIMS & HERS also has a petition on the site, “Congress and FDA to preserve access to combined GLP-1 treatment.” To ensure that the user has an option, he and she provides weight loss drugs that are not affected by this notice, such as METFORMIN, a tablet -based diabetes drug with many other providers.
Some sources may have loopholes in the complex world, but they are very dark.
One source said, “Some remote health staff are listening to talking to it to combine it, but it will be custom.
This may seem to add new ingredients to alleviate extreme side effects. But some experts say that this can be impossible because the FDA predicts that it will be cracked down at any time.
In addition to the company, consumers are faced with a significant risk. Only brand names can be used, so GLP-1 users face at a very high cost. For those who can’t afford drugs anymore, sources say they can gain the most or more weight. There are also concerns that people can rely on unprotected cancer market drugs.
Given these challenges, pharmaceutical manufacturers are trying to respond. For example, Novo Nordisk announced that people in recent pockets will lower the price of drug Wegovy to $ 499 a month. Eli Lilly, meanwhile, dropped the price from a part of a low dose of Zepbound.
SOWA said, “This is a step forward in the right direction. “We must go down to European prices and expand insurance to drug manufacturers.”
This price drop is not enough for many people.
Hallock said, “That’s too expensive.” “You need to find a way to take out the medicine or get a coin.”
As a result of this news, there were several lawsuits filed by the Outsourcing Facilies Association to reverse the ruling of the FDA. The case of Tirzepatide has been rejected, and the case of Semaglutide is still open. According to sources, this type of lawsuit will continue because companies, complex pharmacies, pharmaceutical manufacturers, and GLP-1 users are looking for solutions.
